DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more


Nutrilib.com
A comprihensive source of nutritional information

Lamictal in the Treatment of Post-Herpetic Neuralgia

Information source: George Washington University
Information obtained from ClinicalTrials.gov on November 03, 2008
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Neuralgia, Postherpetic

Intervention: Lamictal in the treatment of Post-Herpetic Neuralgia (Drug)

Phase: Phase 2/Phase 3

Status: Recruiting

Sponsored by: George Washington University

Official(s) and/or principal investigator(s):
Perry K. Richardson, M.D., Principal Investigator, Affiliation: The George Washington University Medical Faculty Associates

Overall contact:
Elizabeth Kingery, RN, Phone: 202-741-2729, Email: ekingery@mfa.gwu.edu

Summary

To assess the efficacy of Lamictal for the treatment of pain and reduction of allodynia in patients with post herpetic neuralgia.

Clinical Details

Official title: Lamictal in the Treatment of Post-Herpetic Neuralgia-A Safety, Efficacy,Randomized, Double Blind, Placebo Controlled, Cross-Over Study

Study design: Randomized, Double-Blind, Placebo Control, Crossover Assignment

Eligibility

Minimum age: 18 Years. Maximum age: 85 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- All patients will be over the age of 18,

- Need to have a diagnosis of Post-Herpetic Neuralgia,

- Minimum of 4 on the Likert Pain Scale,

- If currently taking TCA and/or Gabapentin, need to have been on stable dose for

minimum of 4 weeks

Exclusion Criteria:

- Currently on any antiepileptic drugs (AED), except for Gabapentin.

- Currently taking opioid or unwilling to washout prior to the study,

- Pregnant and lactating,

- Have active severe systemic disease,

- History of Stevens-Johnson syndrome or TEN,

- Clinically significant abnormal lab values,

- Known drug allergy to Lamictal,

- Patients on Fibrates (Tricor and Lopid),

- History of major psychiatric disturbance and substance abuse.

- Valproate due to increase chances of severe rash,

- Lidocaine Patch,

- Use of hormonal contraceptives (birth control pills, patch, ring, injection)

Locations and Contacts

Elizabeth Kingery, RN, Phone: 202-741-2729, Email: ekingery@mfa.gwu.edu

Medical Faculty Associates, Washington, DC, District of Columbia 20037, United States; Recruiting
Elizabeth Kingery, RN, Phone: 202-741-2729, Email: ekingery@mfa.gwu.edu
Additional Information


Last updated: February 22, 2006

Page last updated: November 03, 2008

-- advertisement -- The American Red Cross

We comply with
HONcode standard.
Verify here.
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2008